12:00 AM
Dec 21, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Microplasmin: Phase II started

Thrombogenics began the double-blind, sham-controlled, European Phase II MIVI 5 trial to evaluate 125 µg intravitreal microplasmin in about 100 patients with wet age-related macular degeneration.

Read the full 113 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >